drugset / Trial / NCT00938639

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults

NCT00938639 ↗

Phase 2 Completed 240 enrolled Seqirus
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.

Timeline

Start
2009-07
Primary completion
2009-09
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CSL425 Vaccine 15 ug Intramuscular
Subject CSL425 Vaccine 30 ug Intramuscular

Indications